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Identification of human viral protein-derived ligands
recognized by individual MHCI-restricted T-cell
receptors
Barbara Szomolay1,2, Jie Liu3, Paul E Brown1, John J Miles4, Mathew Clement2, Sian Llewellyn-Lacey2,
Garry Dolton2, Julia Ekeruche-Makinde5, Anya Lissina6, Andrea J Schauenburg2, Andrew K Sewell2,
Scott R Burrows4, Mario Roederer3, David A Price2,3, Linda Wooldridge6,7 and Hugo A van den Berg1,7
Evidence indicates that autoimmunity can be triggered by virus-specific CD8+ T cells that crossreact with self-derived peptide
epitopes presented on the cell surface by major histocompatibility complex class I (MHCI) molecules. Identification of the
associated viral pathogens is challenging because individual T-cell receptors can potentially recognize up to a million different
peptides. Here, we generate peptide length-matched combinatorial peptide library (CPL) scan data for a panel of virus-specific
CD8+ T-cell clones spanning different restriction elements and a range of epitope lengths. CPL scan data drove a protein
database search limited to viruses that infect humans. Peptide sequences were ranked in order of likelihood of recognition.
For all anti-viral CD8+ T-cell clones examined in this study, the index peptide was either the top-ranked sequence or ranked as
one of the most likely sequences to be recognized. Thus, we demonstrate that anti-viral CD8+ T-cell clones are highly focused on
their index peptide sequence and that ‘CPL-driven database searching’ can be used to identify the inciting virus-derived epitope
for a given CD8+ T-cell clone. Moreover, to augment access to CPL-driven database searching, we have created a publicly
accessible webtool. Application of these methodologies in the clinical setting may clarify the role of viral pathogens in the
etiology of autoimmune diseases.
Immunology and Cell Biology (2016) 94, 573–582; doi:10.1038/icb.2016.12
CD8+ T cells recognize antigens in the form of intracellular protein-
derived peptide fragments (8–14 amino acids in length) presented on
the cell surface by major histocompatibility complex class I (MHCI)
molecules. Although this modus operandi enables the elimination of
cancerous or infected cells, dysregulated CD8+ T-cell immunity can
have devastating consequences for the host. For example, it has been
proposed that CD8+ T cells play a major role in the pathogenesis of
common autoimmune diseases, such as type 1 diabetes,1–3 multiple
sclerosis4 and psoriasis,5 where pathogen-derived peptide sequences
are thought to drive the expansion of self-reactive T cells capable of
mediating tissue damage.6,7 This theory is supported by findings that
microbial peptides can induce experimental autoimmune disease in
mouse models and that human autoantigen-specific T cells can
recognize numerous peptides, some of which are microbial in
origin.8,9 Moreover, in certain disease states, the presence of mono-
clonal/oligoclonal CD8+ T-cell expansions with a late-differentiation
phenotype, sometimes referred to as large granular lymphocytes
(LGLs), is suggestive of an exaggerated antigen-specific response.10
Such expansions are a characteristic feature of T-LGL leukemia11–13
and can be triggered by certain drugs, notably protein tyrosine
kinase inhibitors.14,15 CD8+ T-cell expansions are also observed in
autoimmune diseases such as rheumatoid arthritis16 and aplastic
anemia.17 It is possible that viral antigens drive these pathogenic
CD8+ T-cell expansions, which subsequently crossreact with
self-derived peptide-MHCI (pMHCI) molecules to precipitate clinical
disease.
Although it is clear that CD8+ T cells play an important role in
health and disease, relatively little is known about the microbial and
self-derived ligands involved in these processes. This lack of knowledge
can to a large extent be attributed to the complexity of the peptide
repertoire recognized by individual T-cell receptors (TCRs). Estimates
suggest that there are ~ 25 million unique TCRs in the human
repertoire,18 each with the potential to recognize up to 1 million
different MHC-bound peptides.19,20 Such promiscuous recognition
has been deemed essential for effective immunity, as a relatively
limited repertoire of TCRs must provide adequate coverage against a
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vast array of different pMHC molecules.21 Indeed, a given TCR may
not only interact productively with ligands similar to the index peptide
that triggered the initial response, but also with ligands that are
unrelated in sequence,22 indicating that effective characterization of
the cognate ligand repertoire must take the entire peptide universe
into account without bias. A promising approach that satisfies these
desiderata is combinatorial peptide library (CPL) scanning, which can
be combined with biometrical analysis to identify naturally occurring
ligands.23,24
Although the set of peptides recognized by an individual TCR can
be vast, not all of these sequences will be present in the naturally
occurring MHC-presentable peptide repertoire. Novel approaches are
therefore required to identify biologically relevant ligands. Ideally, such
an approach should incorporate: (i) an assessment of peptide length
specificity;25 (ii) an unbiased framework applicable to all TCRs
irrespective of specificity and MHC restriction; (iii) rapid throughput
for clinical applicability; and (iv) an accurate end point for the reliable
classification of response-evoking ligands in vivo.
Here, we develop and validate a strategy to examine the peptide
repertoire recognized by individual MHCI-restricted TCRs. Raw
datasets from length-matched CPL scans were used to rank peptides
occurring in curated databases of viral pathogen or human self origin.
The predictive value of the scoring method was then validated by
measuring functional sensitivity for a selection of peptides spanning a
range of predicted agonist likelihood values. This approach enabled us
to identify the original viral determinant for a CD8+ T-cell response.
We envisage that ‘CPL-driven database searching’ will find clinical
utility across a range of immune-mediated diseases with currently
unknown antigenic triggers.
RESULTS
Development and validation of an effective approach to identify
natural ligands recognized by individual MHCI-restricted TCRs
Pathogenic CD8+ T-cell expansions may originate as an initially
protective response to a viral antigen that results in immune-
mediated disease, caused by subsequent crossreactivity with a self-
derived pMHCI molecule. The need therefore arises to identify viral
ligands that trigger CD8+ T-cell expansions of unknown specificity.
To develop and validate an approach to this problem, we interrogated
a CD8+ T-cell clone (E7NLV) specific for the immunodominant
HLA A*0201-restricted human cytomegalovirus (HCMV) pp65495–503
epitope NLVPMVATV; HCMV is a member of the herpesvirus family
that has been implicated in the pathogenesis of common CD8+ T-cell-
mediated diseases.26
MHCI-restricted TCRs display an explicit preference for peptide
length, as attested by the fact that screening with CPLs of non-
preferred length elicits a minute number of positive responses,
whereas screening with CPLs of the preferred length elicits responses
at every peptide position, allowing the molecular recognition land-
scape for each individual TCR to be mapped in detail.25 Accordingly,
we scanned E7NLV with a nonamer CPL to determine the amino acid
preferences across the peptide backbone. Multiple responses were
observed at the majority of positions, indicative of a crossreactive TCR
with a propensity for degenerate peptide recognition (Figure 1).
Although CPL scan data can be used to perform BLAST or motif-
based searches directly, these approaches generate peptide lists without
quantifying the likelihood of recognition. We took an alternative
approach that uses raw peptide length-matched CPL scan data to
search large protein databases, producing lists of potential peptide
agonists ranked in order of likelihood of recognition. This ranking was
achieved by assigning an agonist likelihood score Λ, as defined below
by equation (8), to each subsequence in a protein database comprising
the majority of known viruses regardless of host tropism.
To validate the accuracy of this approach, 30 peptide sequences
were chosen by uniform sampling without repetition such that
their Λ-values spanned ~ 6 orders of magnitude. Sampling was
implemented using the MATLAB datasample command; when there
were five different peptides in each bin for a given order of magnitude,
the sampling algorithm halted. The peptides were synthesized and a
functional sensitivity assay was performed. Figure 2a shows the
functional response of E7NLV to the 30 selected peptides. A broad
range of recognition was observed, with 15 out of 30 peptides acting as
good agonists and 6 out of 30 peptides acting as strong agonists. The
functional sensitivity of the clone for each peptide was expressed as
pEC50, the common cologarithm of the 50% efficacy concentration.
Relative functional sensitivity (ΔpEC50) was calculated by subtracting
the pEC50 of the index peptide from the pEC50 of the given peptide
(Figure 2b). We examined the statistical dependence between Λ and
ΔpEC50 for all 30 randomly chosen peptides using Spearman’s rank
correlation test. The correlation for the peptides shown in Figure 2c
was 0.49, which is significant at the 2% level, and the corresponding
linear regression of ΔpEC50 on Λ was significant at the 1% level. These
results demonstrate that CPL-driven database searching can accurately
identify peptide sequences recognized by individual TCRs.
Figure 1 Nonamer CPL scan of E7NLV. 6×104 C1R-A*0201 target cells were pulsed in duplicate with mixtures from a 9-mer CPL scan (100 μM) at 37 °C.
After 2 h, 3×104 E7NLV CD8+ T cells were added and incubated overnight. The supernatant was then harvested and assayed for MIP1β by ELISA.
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CPL-driven database searching can identify viral ligands that
initiate CD8+ T-cell responses
We next assessed whether our approach could be used to identify the
original viral ligand that drove the initial expansion of a given
clonotype, independently of prior knowledge of this ligand or the
identity of the infectious agent. For this purpose, we constructed a
database containing all human viral pathogens, as well as all zoonotic
viruses capable of or suspected to be capable of infecting humans, to
the best of our knowledge and judgement. Each of the 1 872 417
unique nonamer peptide sequences in this database of 10 733 distinct
viral proteins was assigned a Λ-value according to equation (8), with
parameter values derived from a nonameric CPL scan of clone
E7NLV. These sequences were ranked by Λ, which represents the
likelihood of recognition by this clone. The index peptide for E7NLV,
NLVPMVATV, was found to be the top-ranked sequence, suggesting
that CPL-driven database searching alone can suffice to identify
the infectious agent (Figure 3 and Supplementary Table S1A).
We then examined the functional response to a further nine top-
ranking peptides. In addition to the index, which had been recovered
without prior knowledge, five out of the further nine predicted
peptides were capable of activating E7NLV, with three being strong
agonists (Figure 3). Thus, CPL-driven database searching could select
from a comprehensive database not only the pathogen-derived
sequence that had driven the initial expansion of clone E7NLV, but
also a variety of crossreactive peptide ligands.
CPL-driven database searching can identify viral ligands recognized
by EBV-specific CD8+ T cells
To extend the foregoing findings to other specificities, we examined a
panel of Epstein–Barr virus (EBV)-specific CD8+ T-cell clones. EBV
has been implicated in the pathogenesis of autoimmune diseases such
as multiple sclerosis.27 Our knowledge regarding the etiology of these
diseases would therefore be advanced by a method that can define
antigen specificity within the associated CD8+ T-cell clonal
expansions.28 We initially focused on clones SB16 and SB12, which
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Figure 2 Recognition of 30 randomly chosen and uniformly distributed peptides by the E7NLV clone. (a) 1×103 C1R-A*0201 target cells per condition
were pulsed with a panel of 30 peptides over a range of concentrations in duplicate for 1 h at 37 °C. 2×103 E7NLV CD8+ T cells were then added to
achieve an E/T ratio of 2:1. Cytotoxic activity was measured via chromium release from C1R-A*0201 target cells as described in the Methods. (b) Relative
functional sensitivity (ΔpEC50) for the same 30 peptides compared with index (ΔpEC50=0). (c) Scatter plot of ΔpEC50 versus Λ for the same 30 peptides.
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are both specific for the immunodominant HLA A*0201-restricted
BMFL1280–288 epitope GLCTLVAML (Table 1).
A nonamer CPL scan of the SB16 clone revealed multiple hits across
the peptide backbone with dominant responses at each position
(Figure 4 and Supplementary Figure S1). The raw CPL scan dataset
was used to conduct a CPL-driven search of the human viral database.
Supplementary Table S1B lists the nonameric peptide sequences
ranked as the 20 sequences most likely to be recognized out of a
database of 1 872 417 different nonameric sequences. The index
peptide sequence for this clone was found to have the largest Λ-value,
consistent with the result obtained for E7NLV (Supplementary
Table S1A). We next performed a nonamer CPL scan with clone
SB12 (Table 1). In contrast to the result obtained with SB16, we did
not detect responses that rose substantially above background, except
at position 8, where a response to methionine was observed
(Supplementary Figure S2); these results were too scanty to permit a
meaningful CPL-driven database search and suggest that SB12 is
highly ligand-specific, recognizing only a small number of peptides.
This characteristic may be shared with other anti-viral CD8+ T cells, as
we observed a similar result with ALF3, a CD8+ T-cell clone specific
for the immunodominant HLA A*0201-restricted influenza A M158–66
epitope GILGFVFTL (Table 1 and Supplementary Figure S3).
CD8+ T cells specific for longer epitopes play a major role
in the response against EBV.29 We therefore examined two
well-characterized clones with different EBV-derived peptide length
preferences. Clone SB14 is specific for the immunodominant HLA
B*3508-restricted EBNA1407–417 epitope HPVGEADYFEY (Table 1).
Accordingly, we performed an 11-mer CPL scan on this clone
(Figure 4 and Supplementary Figure S4). A CPL-driven search of
the human viral database predicted that the 2 most likely recognized
11-mer peptide sequences were HPVAEADYFEY and HPVGDADYFEY
(4A and 5D variants of the index peptide), with the index peptide itself
ranking third in the list (Supplementary Table S1C). Clone
SB27 is specific for the HLA B*3508-restricted BZFL152–64 epitope
LPEPLPQGQLTAY and exhibits a strong preference for 13-mer
peptides.25 A 13-mer CPL scan of this clone revealed a high degree
of crossreactivity (Ekeruche-Makinde et al.25 and Figure 4), but
notwithstanding this apparent promiscuity, the index peptide still
ranked twelfth in a CPL-driven search of the human viral database
(Supplementary Table S1D).
Collectively, these findings demonstrate that viral peptide
specificities can be identified efficiently by means of peptide length-
matched CPL-driven database searching. In general, anti-viral CD8+
T cells appear to be highly focused on their index peptide sequence,
albeit with an inherent degree of crossreactivity.
CPL-driven database searching can identify variants recognized by
HIV-1-specific CD8+ T cells
To examine the utility of CPL-driven database searching in other viral
infections, we studied two previously described TCRs specific for the
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Figure 3 E7NLV recognition of the top 6 peptides (a) and peptides ranked 7–10 (b) from the human pathogen database. In b, peptide recognition is
compared with index (black upside–down triangles). Cytotoxic activity was measured via chromium release from C1R-A*0201 target cells as described in the
Methods.
Table 1 CD8+ T-cell clones used in this study
Clone ID Specificity HLA restriction Minimal epitope Peptide length Reference
E7NLV HCMV A*0201 NLVPMVATV 9 a
SB16 EBV A*0201 GLCTLVAML 9 a
SB12 EBV A*0201 GLCTLVAML 9 a
ALF3 Influenza A A*0201 GILGFVFTL 9 Clement et al.41
SB14 EBV B*3508 HPVGEADYFEY 11 Miles et al.42
SB27 EBV B*3508 LPEPLPQGQLTAY 13 Tynan et al.43
003 HIV-1 A*0201 SLYNTVATL 9 Goulder et al.44
868 HIV-1 A*0201 SLYNTVATL 9 Goulder et al.44
ILA1 Telomerase A*0201 ILAKFLHWL 9 Laugel et al.45
MEL5 Melan-A A*0201 ELAGIGILTV 10 Cole et al.46
Abbreviations: EBV, Epstein–Barr virus; HCMV, human cytomegalovirus; HIV, human immunodeficiency virus; TCR, T-cell receptor.
aFirst description of this CD8+ T-cell clone. The parental clone was used in all cases except for 868, where primary CD8+ T cells were transduced to express the 868 TCR.
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immunodominant human immunodeficiency virus type 1 (HIV-1)-
derived HLA A*0201-restricted p17 Gag77–85 epitope SLYNTVATL
(Table 1). Consistent with the results above, a CPL-driven search of
the human viral database using nonamer CPL scan data from the 003
clone identified the index sequence as the most likely agonist (Figure 4
and Supplementary Figure S5; Supplementary Table S1E). Moreover,
a number of epitope variants were predicted, many of which have
been verified at the functional level.30,31 Similar results were obtained
with the 868 TCR, in this case scanning primary CD8+ T cells
transduced with the corresponding lentiviral construct (Figure 4 and
Supplementary Figure S6; Supplementary Table S1F). CPL-driven
database searching can therefore predict epitope variant crossreactivity
patterns, which may prove useful in the assessment of CD8+ T-cell
responses against highly variable viruses.
Extending the approach to the identification of self ligands targeted
by CD8+ T cells
In addition to the identification of virus-derived epitopes, it would be
advantageous if CPL-driven database searching could reveal self-
derived peptide targets, as this would provide a means to identify
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Figure 4 Heat maps summarizing CPL scan data for: E7NLV (a), SB16 (b), SB14 (c), SB27 (d), 003 (e), 868 (f), ILA1 (g) and MEL5 (h). CPL scan data are
normalized in each row so that the values range from high (red) to low (blue); the maximum intensity is the largest of all red values in the rows. Amino acids
are grouped according to their physicochemical properties as follows: polar, uncharged amines: Q, N; polar, uncharged alcohols: T, S; small: G, A, C;
hydrophobic: A–H; aliphatic: V, I, L; aromatic: Y, F, W, H; large: F, W; charged basic: H, K, R; and charged acidic: E, D.
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the antigenic proteins involved in autoimmune diseases and, more-
over, to discover novel cancer epitopes recognized by CD8+ T cells. To
this end, we created a human protein database as described below. The
CD8+ T-cell clones ILA1 and MEL5 were chosen because they are
both specific for epitopes derived from self proteins. In particular,
ILA1 is specific for the HLA A*0201-restricted human telomerase
reverse transcriptase (hTERT)540–548 sequence ILAKFLHWL (Table 1).
A nonamer CPL scan previously carried out for ILA125,32 was used to
conduct a CPL-driven search of the human protein database
(Figure 4). The index peptide was ranked by Λ as the eighth most
likely nonameric peptide sequence to be recognized by the ILA1 TCR,
suggesting that this approach is capable of identifying self-derived
ligands targeted by TCRs (Supplementary Table S2A).
However, a previous study indicated that ILAKFLHWL is not
expressed at the cell surface,33 and therefore ILA1 may not be typical
of a self-reactive TCR that has survived negative selection. To
address this potential confounder, we studied MEL5, which recognizes
the HLA A*0201-restricted Melan-A epitope EAAGIGILTV.34
A nonamer CPL scan, which had previously been carried out for
MEL5,25,34 was used to conduct a CPL-driven search of the human
protein database (Figure 4). The EAAGIGILTV sequence did not
appear in the top 20 peptides predicted to activate MEL5 (EAAGI-
GILTV ranked fifty-fifth; Supplementary Table S2B). It is possible that
self-reactive TCRs are not focused on their index peptide to the same
degree as virus-specific TCRs and, consequently, the CPL-driven
database searching approach may fail to identify disease-relevant
ligands targeted by self-reactive TCRs. The use of smaller disease-
specific or organ-specific databases might improve the applicability of
our strategy in this context.
Overview of CPL-driven database screening and development of a
webtool
Every TCR is characterized by a unique peptide recognition signature,
which comprises three different components: (i) a peptide length
preference; (ii) the number of peptides recognized at this preferred
length; and (iii) the sequence identity of these peptide agonists, which
may be either pathogen-derived or self-derived.20,25 Figure 5 provides
an overview of a three-stage strategy to dissect the peptide recognition
signature of a given TCR. In the first stage, peptide length preference is
determined by examining functional recognition of a ‘sizing scan’
comprising random peptide libraries of different lengths (x8, x9, x10,
x11, x12, x13, where x denotes any of the 19 L-amino acids excluding
cysteine).25 In the second stage, CPL-biased sampling19 is used to
quantify the number of recognized peptides. In the third stage, which
is the novel step introduced in the present study, CPL-driven database
searching is used to identify antigen specificity. To augment
community-wide access to CPL-driven database searching, we created
a dedicated webtool as part of the WSBC webtools framework.
DISCUSSION
Although CD8+ T cells protect the human body from countless
intracellular pathogens and malignant processes, they are also heavily
implicated in the etiology of life-threatening and incurable immune-
mediated diseases. It is conceivable that non-self antigens elicit CD8+
T-cell responses that are initially target-appropriate but subsequently
become pathogenic as a consequence of crossreactivity with self
epitopes. In this study, we developed and validated a technique
termed ‘CPL-driven database searching’, which allows for the reliable
identification of cognate viral epitopes recognized by CD8+ T cells
with as yet unknown specificities. Initially, we constructed a viral
database containing human and zoonotic viruses (with an established
or potential ability to infect humans). This database was curated to
include non-redundant and reviewed sequences only and contained a
total of 10 733 viral proteins. We then selected a panel of herpesvirus-
specific CD8+ T-cell clones spanning two different restriction elements
(HLA A*0201 and HLA B*3508) and a range of epitope lengths
(9–13 amino acids). As CD8+ T cells typically display an explicit
preference for peptide length,25 we focused our attention on peptide
length-matched CPL scans to determine the amino acid preferences of
each clone at each peptide position. The majority of clones in our
panel elicited strong responses with distinct preference hierarchies at
each position of the peptide. CPL scan datasets were used to assign an
agonist likelihood score (Λ) to each peptide of preferred length in the
entire human viral database, thereby producing a list of potential
peptide ligands in order of likelihood of recognition. For all
herpesvirus-specific clones tested, the index epitope ranked in the
top 20 most likely recognized peptide sequences from the entire
human viral database, even for the highly crossreactive CD8+ T-cell
clone SB27, which is specific for an EBV-derived HLA B*3508-
restricted 13-mer epitope. These findings indicate that anti-viral CD8+
T cells display high levels of functional sensitivity for the index
epitope, consistent with an efficient in vivo selection process based on
interclonal competition for antigen.35
It is noteworthy that one EBV-specific CD8+ T-cell clone failed to
respond to any CPL scan mixtures except M@8 and was therefore not
suitable for further analysis. This difficulty could be emblematic of a
small subset of CD8+ T-cell clones that are highly focused on the
salient ligand and therefore fail to respond to a sufficiently large
number of peptides within the CPL mixtures. CPL-driven database
searching is not applicable to such TCRs, which behave as ‘non-
responders’ in the context of a CPL scan. Moreover, to ensure the
accuracy of CPL-driven database searching, experimental CD8+ T-cell
populations must be monoclonal and must be subjected to multiple
replicates of each scan.
The viral pathogen and human proteome databases were collated
and curated with a view to making them as exhaustive as possible. It
may be considered that the relatively small size of the former database
contributes to the success of our method, but this is not the case.
Indeed, when the two databases were merged, comparable rankings
were obtained. In terms of relative rank, the merged database was
slightly better for most TCRs, indicating that the ranks derived from
the viral database are actually more conservative. Notwithstanding
these advantages, the identification of relevant epitopes in the human
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Figure 5 Three-stage strategy to dissect the peptide recognition signature of
individual TCRs. To augment community-wide access to CPL-driven database
searching, we have created a dedicated webtool as part of the WSBC
webtools framework.
Identifying natural CD8+ T-cell agonists
B Szomolay et al
578
Immunology and Cell Biology
proteome database is much more challenging, likely due to the fact
that even physiologically relevant autoimmune epitopes are typically
recognized at low levels of functional sensitivity. Work is in progress to
build and test similar databases for bacterial and fungal pathogens.
These will be added to the webtool on completion.
It is known that HIV-1 can escape from the CD8+ T-cell response
via single point mutations in key epitopes.36 If CD8+ T cells are
inherently crossreactive, why does the HIV-1-specific CD8+ T-cell
response exhibit such exquisite specificity? Our findings point to a
possible explanation. The HIV-1-specific TCRs examined in this study
(003 and 868) were strongly focused on their index peptide sequence,
increasing the probability that epitope mutation will result in loss of
recognition. In contrast, CD8+ T cells with a more crossreactive
phenotype are associated with delayed disease progression.37,38 It is
therefore feasible that CPL-driven database searching will provide a
useful tool to delineate the requirements for effective CD8+
T-cell-mediated immunity against HIV-1.
CPL-driven database searching may also assist in the identification
of self-derived epitopes, such as those targeted by autoimmune or
cancer-specific CD8+ T cells. Indeed, similar approaches to ligand
hunting in these settings have been described previously.39,40 Although
we successfully identified the index peptide for the ILA1 clone, it has
been shown that the cognate epitope is not expressed on the surface of
HLA A*0201+ hTERT+ cancer cell lines,33 which renders it less likely
that this epitope is expressed in the thymus. If so, ILA1 will not have
been subjected to negative selection in the thymus, which could
account for the highly focused phenotype of this clone. In contrast, the
index EAAGIGILTV peptide recognized by the MEL5 clone was
ranked at position 55. It may therefore be more challenging to identify
bona fide self-derived epitopes that are expressed in the thymus.
Generation of disease-specific or organ-specific protein databases
might circumvent this problem by narrowing the search for relevant
epitopes, but further work is required to test such focused screening
strategies.
In summary, we have developed and validated an approach that can
be used to dissect the peptide recognition signature of any given TCR.
Accordingly, we anticipate that CPL-driven database searching will
find clinical utility across a range of diseases.
METHODS
Cells
Ten human CD8+ T-cell clones spanning eight different specificities were used
in this study (Table 1). The index peptides for the following CD8+ T-cell clones
are derived from viral proteins: E7NLV, SB16, SB12, ALF3,41 SB14,42 SB27,43
00344 and 868.44 The index peptides for the remaining two CD8+ T-cell clones,
ILA145 and MEL5,46 are derived from human self proteins. Clone E7NLV is
specific for the HLA A*0201-restricted HCMV-derived pp65 epitope
NLVPMVATV (residues 495–503). Four clones are specific for epitopes derived
from EBV proteins: SB16 and SB12, which both recognize the HLA A*0201-
restricted BMLF1 epitope GLCTLVAML (residues 280–288); SB14, which
recognizes the HLA B*3508-restricted EBNA1 epitope HPVGEADYFEY
(residues 407–417); and SB27, which recognizes the HLA B*3508-restricted
BZLF1 epitope LPEPLPQGQLTAY (residues 52–64). Clone ALF3 is specific for
the HLA A*0201-restricted influenza A-derived M1 epitope GILGFVFTL
(residues 58–66; Clement et al.41). The 003 and 868 TCRs are both specific
for the HLA A*0201-restricted HIV-1-derived p17 Gag epitope SLYNTVATL
(residues 77–85). Clone ILA1 is specific for the HLA A*0201-restricted
hTERT-derived sequence ILAKFLHWL (residues 540–548), and clone MEL5
is specific for the Melan-A-derived heteroclitic sequence ELAGIGILTV
(residues 26–35). All CD8+ T cells were maintained in RPMI 1640 containing
100 U ml− 1 penicillin, 100 mg ml− 1 streptomycin, 2 mM L-glutamine and 10%
heat-inactivated fetal calf serum (all Life Technologies, Paisley, UK),
supplemented with 2.5% Cellkines (Helvetica Healthcare, Geneva, Switzerland),
200 IU ml− 1 interleukin (IL)-2 and 25 ng ml− 1 IL-15 (both PeproTech, Rocky
Hill, CT, USA). C1R-A*0201 and T2-B*3508 target cells were generated and
maintained as described previously.47
CPL scans
CPL libraries were synthesized in a positional scanning format (Pepscan Presto
Ltd, Lelystad, Netherlands). All CPL scans were performed as described
previously.19,25,32 Briefly, 6 × 104 target cells were incubated with various library
mixtures (at 100 μM) in duplicate for 2 h at 37 °C. After peptide pulsing, 3 × 104
clonal CD8+ T cells were added and the plates were incubated overnight to 37 °
C. Supernatants were then collected and assayed for MIP1β content by enzyme-
linked immunosorbent assay (ELISA; R&D Systems, Abingdon, UK).
Functional sensitivity assays
For MIP1β ELISA assays, 6 × 104 target cells were pulsed with peptide at the
indicated concentrations for 2 h at 37 °C. Subsequently, 3 × 104 clonal CD8+
T cells were added and the plates were incubated overnight at 37 °C.
Supernatants were then collected and assayed for MIP1β by ELISA. For lysis
assays, target cells were loaded with 51Cr for 1 h and then plated at 5000 cells
per well in 75 μl medium. Clonal CD8+ T cells were added to a total volume of
150 μl. Target cells alone were used to measure spontaneous release and Triton
X-100 was used to measure total release. After incubation for 4 h at 37 °C, 15 μl
supernatant per well was harvested and mixed with 150 μl OptiPhaseSupermix
Scintillation Cocktail (Perkin-Elmer, Waltham, MA, USA). Release of 51Cr was
measured with a Microbeta Counter (Perkin-Elmer) and the resulting data were
used to calculate % specific lysis according to the formula:
Experimental release spontaneous release
Total release spontaneous release ´ 100%
Functional sensitivity was determined as described previously;19 it is expressed
as pEC50, the cologarithm to base 10 of the 50% efficacy concentration as
determined from dose–response experiments in which antigen-presenting cells
were incubated with agonist across a series of dilutions.
Derivation of the agonist likelihood score method
The functional sensitivity of a clone of interest to a given peptide ligand
depends on several factors, a key parameter being the rate at which a single
pMHCI copy elicits TCR triggering.48,49 We quantify TCR degeneracy as the
probability that the functional sensitivity of a given TCR to a randomly chosen
ligand exceeds a given value ω;50 this probability expresses the degeneracy at ω.
Let wij denote the functional sensitivity of TCR i to peptide j, where wijpw^ for
all i and j (with w^40). Besides being a function of TCR i and pMHCI species j,
functional sensitivity depends on additional factors such as cellular differentia-
tion and coreceptor expression; we assume such additional parameters to be
uniform across the experiments performed in the present study. If n is the
length of the peptides considered, then 20n is the size of the peptide universe
(the total number of distinct peptides). Given a peptide subset S of the peptide
universe, the general question of epitope prediction can be framed as follows:
for a clone of interest i, determine the quantity ℙ wij4ojjAS
 
, that is, the
probability that wij exceeds a set value oA½0; w^, when it is known that the
peptide ligand j belongs to this set S. For a peptide j selected at random, we
have ℙ jAS½  ¼ 20n Sj j, where Sj j denotes the cardinality of S. Then, by
Bayes’ Rule,
ℙ wij4ojjAS
  ¼ ℙ jASjwij4o ℙ wij4o
 
ℙ jAS½ 
¼ ℙ jASjwij4o
 
ℙ wij4o
 
20n Sj j1 ; ð1Þ
which expresses the problem in the empirically more accessible probability
ℙ jASjwij4o
 
, that is, the chance that a randomly selected peptide j belongs
to S, given that the functional sensitivity wij to this peptide is at least ω. A direct
estimate of this probability could be obtained by subjecting randomly generated
peptides to a functional sensitivity assay and verifying whether they also belong
to S. However, this would be highly inefficient and would require millions of
random peptides to be reasonably accurate, as the vast majority would be
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practically ‘null’ (that is, having pEC50 well below the detection limit). More
progress can be made provided that S is a cylinder, which is a special type of
set, defined as follows: let 1pp1op2o:::opkpn represent a choice of
positions in the peptide and let a1; a2; :::; ak be a choice of amino acid residues
for these positions (several or all of these αs could be the same amino acid).
Then a peptide set of the form
Cp1 ;:::;pka1 ;:::;ak ¼ peptides such that the residue at position pr is ar for r ¼ 1; :::; k
 
is called a cylinder of rank k. For example, the rank-2 cylinder C4;5Q;R contains all
and only the peptides with glutamine at position 4 and arginine at position 5.
The cardinality of a rank-k cylinder is 20n− k; in particular, the rank-0 cylinder
is the entire peptide universe, as no amino acids are specified at any position,
whereas a rank-n cylinder contains just one peptide, all positions having been
specified.
Given a rank-k cylinder Cp1 ;y;pka1 ;y;ak , let J denote a subset of fp1;y; pkg, and letCJa½J be the lower-order cylinder which has amino acids specified only at the
positions in J, agreeing with the ‘parent’ Cp1 ;y;pka1 ;y;ak at those positions, that is, CJa½J
is formed by dropping from Cp1 ;y;pka1 ;y;ak the positions not present in J. Let c be an
integer 0pcpk, and let ðfp1 ;y;pkgc Þ denote the set of all subsets J of size c, so
that cylinders can be decomposed as follows:
Cp1 ;y;pka1 ;y;ak ¼ UJA fp1;y; pkg
k 1
 CJa½J: ð2Þ
Next, let correlation functions be defined recursively, as follows:
Kp1 ;y;pka1 ;y;ak o; ið Þ ¼
20kP½jACp1 ;y;pka1 ;y;ak jwij4oQk1
c¼0
Q
JA
fp1;y; pkg
c
  KJa½J o; ið Þ
ð3Þ
with lowest-order boundary condition Kðo; iÞ  1 for all oA½0; w^. The
correlation functions permit an exact solution of the epitope prediction
problem, since equation (3) implies that
P½jACp1 ;y;pka1 ;y;ak jwij4o ¼ 20k
Yk
c¼1
Y
JA
fp1;y; pkg
c
  KJa½Jðo; iÞ ð4Þ
and with equation (1) this can be transformed into the probability that a
peptide is an agonist with functional sensitivity of at least ω, given that the
peptide belongs to some cylinder of interest, which might be of appropriate
cardinality, be this almost the entire peptide universe or a singleton set (that is,
a rank-n cylinder containing only that peptide).
The crucial step is to establish a connection to CPL data. Consider the CPL
mixture K@3, in which lysine is fixed at position 3 with all other positions
random. This mixture corresponds to the rank-1 cylinder C3K. Similar
correspondences obtain for all 180 CPL mixtures (in the case n= 9). Suppose
that a peptide contributes appreciably to the CPL read-out whenever wij exceeds
a certain cut-off value ~o, let Y apðiÞ denote the read-out signal obtained when
exposing clone i to the mixture α@p, and let A denote the set of 20 amino
acids. We then propose the following identification:
P jACpajwij4~o
  ¼ Y
a
pðiÞP
a0AAY
a0
p ið Þ
ð5Þ
where p is the single specified position (with 1pppn) and α is the specified
amino acid residue at this position. The rank-1 specialization of equation (3) is
as follows:
ℙ jACpajwij4o
  ¼ 1
20
Kpa o; ið Þ ð6Þ
and thus, with ω set to ~o, equation (5) provides a way to estimate the lowest-
order correlation function from the CPL scan data. The proposed identification,
equation (5), rests on somewhat idealized assumptions, since peptides with wij
values below ~o may still contribute if they are presented at high copy numbers
on the antigen-presenting cell and, conversely, peptides with high wij values
may fail to contribute substantially.
In principle, higher-rank correlation functions can be estimated from higher-
rank CPLs, which contain library mixtures corresponding to higher-rank
cylinders (for example, the mixture K@3&A@5 corresponds to the rank-2
cylinder C3;5K;A), but the number of peptide mixtures required, and hence the
cost of the experiment, quickly becomes prohibitive. Rank-1 correlations can
nevertheless be informative as long as higher-order correlations do not
dominate. Mathematically speaking, the higher-order correlations are neglected
by setting the corresponding K-values equal to 1; this amounts to a truncation
of the exact expansion in equation (4). Combining equations (1) and (5) with
the truncated version of equation (4), we obtain the following for a specified
peptide a1a2?an:
ln P wij4~ojpeptide j is a1a2?an
 
Eln Pið~oÞ þ n ln 20f g þ
Pn
p¼1
ln
Y
ap
p ðiÞP
a0AAY
a0
p ðiÞ
where Pið~oÞ is the unconditional probability that the functional sensitivity
of clone i for a peptide selected at random exceeds ~o. For the purpose of
ranking peptides, we can proceed without knowing the value of Pið~oÞ, since it
merely represents a fixed offset term, once a clone has been fixed. We therefore
retain only the last term in equation (7), which we call the agonist likelihood
score:
L a1a2?an; ið Þ ¼
Xn
p¼1
ln
Y
ap
p ðiÞP
a0AAY
a0
p ðiÞ
: ð8Þ
MATLAB scripts were written to scan the human and viral pathogen databases
and to evaluate Λ for all potential peptides of the clone-appropriate length in
the proteomes (that is, all subsequences of the specified length irrespective of
antigen processing constraints). Excluded were those containing one or more
unspecified residues, appearing as X in the databases; such cases were rare.
NetChop predictions of MHCI binding were also obtained via the publicly
available online tool, but these data are not reported here because we did not
find that they winnowed the candidate peptide list.
Data access provisions
Databases. Human and viral databases were compiled on the basis of publicly
available protein sequence databases provided by NCBI (National Center for
Biotechnology Information), UniProt (Universal Protein Resource) and PDB
(Protein Data Bank).
The human proteome database was assembled using protein sequence
information taken from the following data sources:
(i) File protein.fa.gz from
ftp://ftp.ncbi.nih.gov/genomes/Homo_sapiens/protein/;
(ii) File human.protein.faa.gz from
ftp://ftp.ncbi.nih.gov/refseq/H_sapiens/mRNA_Prot/;
(iii) http://www.uniprot.org/uniprot/ for canonical and isoform sequence
data in FASTA format (Protein Knowledgebase search terms: organism:homo
sapiens and reviewed:yes);
(iv) http://www.pdb.org/pdb/home/home.do for human protein sequences
(search terms: taxonomy:homo sapiens, polymer type:protein, custom tabular
report:sequence, macromolecular name, source).
The viral protein database was assembled using protein sequence
information taken from the following data sources:
(i) file viral.1.protein.faa.gz from
ftp://ftp.ncbi.nih.gov/refseq/release/viral/;
(ii) file all.faa.tar.gz from
ftp://ftp.ncbi.nih.gov/genomes/Viruses;
(iii) http://www.uniprot.org/uniprot/ for canonical and isoform sequence
data in FASTA format (Protein Knowledgebase search terms: host:human and
reviewed:yes);
(iv) http://www.pdb.org/pdb/home/home.do for viral protein sequences
(search terms: taxonomy:viruses, polymer type:protein, custom tabular
report:sequence, macromolecular name, source).
(Remote file names and locations may be subject to change).
The assembled databases were curated to contain non-redundant and
certified sequences, comprising 54 886 human and 187 840 viral proteins,
respectively. As the viral database was compiled from a variety of data sources,
care was taken to ensure that each pathogen was identified by a unique key and
(7)
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that different keys for the same pathogen used in different sources were slaved
to the master key. A list of ~ 250 viral species with known or potential ability to
infect humans was compiled and used to restrict the viral database to pathogens
that infect humans; avoidance of ambiguity poses a major challenge in the face
of issues surrounding the distinction of closely related species of viral pathogens
and the frequent use of alternative designations. Ultimately, there were 10 733
non-redundant protein sequences in the database of proteomes of viral
pathogens that pose a potential danger to human beings.
Webtool. A novel webtool, PI CPL, was written in MATLAB and compiled
using the MATLAB Compiler. The binary code was integrated into the WSBC
webtools framework, accessible at http://wsbc.warwick.ac.uk/wsbcToolsWebpage.
The framework provides a browser-based user interface, from which jobs are
launched and run on a multicore computational cluster. Feedback on progress is
provided via a webpage if required. Results are presented as a webpage and can
also be downloaded for offline viewing. In the case of PI CPL, these consist of a
text file containing a list of the top-scoring peptides, which is designed to be
viewed as a spreadsheet, plus a heat map image. A database of results is
maintained as a job history for logged-on users. To request an account, please
e-mail the corresponding author.
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